Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Aortic Stenosis with High Gradients and Area >1: Just Follow Up?

Definig severe aortic stenosis (AS) rests upon Doppler parameters, and uses log-established cutoff values, which include peak velocity (PV) ≥ 4 m/s, mean gradient (MG) ≥ 40 mmHg and aortic valve area (AVA) ≤ 1 cm². However, there are value discrepancies in up to 30-40% of cases, which has given way to different clinical profiles. 

angulación aórtica post TAVR

One of the discrepant phenotypes corresponds to patients with high gradients (HG) and AVA > 1 cm². Their management and prognosis has hardly been approached by clinical guidelines. The aim of this study was to look into the clinical and hemodynamic characteristics of this group and compare their mortality against other AS subtypes. 

This was a retrospective study on echocardiographic data from the Mayo Clinic (Minnesota, EE. UU.). It included patients with AS diagnosis classified according to AVA, PV and MG into four groups. Patients with prior valve surgery, left ventricular outflow tract obstruction, mitral or aortic insufficiency or mitral stenosis were excluded. Primary outcome was all cause mortality. 

Data from 3,209 were collected, distributed by hemodynamic characteristics as follows: 7.2% phenotype AG-AVA > 1, 45.9% phenotype HG-AVA ≤ 1, 14.3% low gradient phenotype with AVA ≤ 1 (LG-AVA ≤ 1), and 32.6% moderate AS.

HG-AVA > 1 patient mean age was 70.2 ± 12 years, making this the youngest of subtypes (P < 0.01), also presenting higher prevalence of male sex (85.7%), larger body surface and body mass index (BMI), and higher incidence of bicuspid aortic valve (39.6%). They had fewer comorbidities and lower levels of natriuretic peptide type B (BNP). PV and MG values were lower vs. phenotype AVA ≤ 1 (P < 0.01), while 115.0 ± 19 mL systolic volume (SV) and 54.8 ± 10.5 mL/m² indexed value (SV index) were higher.

Read also: SCAAR Registry: Coronary Angioplasty in Venous Grafts.

During a 944-day followup, there were 1,523 deaths (47.5%). Phenotype HG-AVA > 1 presented 38.9% mortality rate at 5 years, and 59.6% at 8 years. After adjusting for age, mortality in this group resulted similar to that of moderate AS patients, but lower vs. phenotype LG-AVA ≤ 1 (HR: 1.9 [CI 95%: 1.4-2.4]; P < 0.01).

As regards aortic valve replacement (AVR), mainly surgical (12.9% were TAVR), 67.4% of patients with HG-AVA > 1 were treated, vs. 69% of HG-AVA ≤ 1, 32.8% of LG-AVA ≤ 1 and 34.7% of moderate AS patients. Mortality in AVR patients, resulted higher in patients with AVA ≤ 1, both for HG (HR: 1.5 [CI 95%: 1.1-2.0]; P = 0.03) and LG patients (HR: 2.4 [CI 95%: 1.6-3.5]; P < 0.001).

Mortality rate for patients with HG-AVA > 1 undergoing AVR was superior to that of one controlled matched population, but significantly lower to that of HG-AVA > 1 patients not operated on (mortality rate 8.2 [CI 95%: 5.9-11.2]).

Conclusions

In this cohort of patients with AS, individuals with high gradients and > 1 cm² valve area were characterized for being younger, and have lower comorbidities vs. other phenotypes. Presented higher survival, expect for a matched population. Aortic valve replacement showed an 8-year survival benefit vs. the non-treated, which suggests a positive impact of surgery for this specific group. 

Original Title: High-Gradient Aortic Stenosis With Valve Area >1.0 cm2 The “Forgotten” Discordant Hemodynamic Phenotype.

Reference: Ito S, Oh JK, Michelena HI, Egbe AC, Connolly HM, Pellikka PA, Nkomo VT, Lewis BR, Miranda WR. High-Gradient Aortic Stenosis With Valve Area >1.0 cm2: The “Forgotten” Discordant Hemodynamic Phenotype. JACC Cardiovasc Imaging. 2024 Sep 5:S1936-878X(24)00315-2. doi: 10.1016/j.jcmg.2024.07.025. Epub ahead of print. PMID: 39297851.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...